For years, Cell Therapeutics CEO Jim Bianco has boasted about the company's long-standing relationship with Novartis. But as of this morning, the relationship is history.
Cell Therapeutics got some good news from the FDA to start 2014. The agency has lifted a partial hold on tosedostat (IND 075503), giving the Seattle-based biotech a green light for all clinical studies of the cancer drug.
Long-troubled biotech Cell Therapeutics has landed a big-name partner for its Phase III myelofibrosis drug, convincing Baxter to shell out $60 million upfront for a cut of pacritinib.
Cell Therapeutics today announced that the FDA had put a partial clinical hold on its study of the experimental blood cancer drug tosedostat after the death of one of the patients in a clinical trial.
In addition to the $30 million upfront for the Singapore-based biotech, CEO Jim Bianco committed the company to an unspecified set of milestones for the treatment.
Two years after Cell Therapeutics ($CTIC) took one of the worst regulatory beatings of the decade at the time the FDA and its experts rejected the company's cancer drug pixantrone, the Seattle-based
Bruised and battered by its setback on pixantrone, Cell Therapeutics ($CTIC) is adding a new drug to its pipeline, paying $5 million upfront to license the North, Central and South American rights to
Cell Therapeutics has raised $25 million by granting preferred stock and warrants to a single unnamed institutional investor. In a statement, the company says it intends to use the net proceeds from
Cell Therapeutics said today that, as planned, it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory
NASDAQ is giving Cell Therapeutics ($CTIC) another 180 days to regain compliance with Nasdaq's $1.00 minimum bid price rule. This is Cell Therapeutics second warning; In early May, Nasdaq notified